Cidara Therapeutics Inc (NASDAQ:CDTX) has been assigned an average recommendation of “Hold” from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $7.60.
A number of equities analysts have commented on CDTX shares. Oppenheimer set a $11.00 target price on ArQule and gave the company a “buy” rating in a report on Wednesday, June 5th. Cantor Fitzgerald reissued an “overweight” rating and set a $130.00 target price (up previously from $116.00) on shares of Zoetis in a report on Wednesday, June 12th. Zacks Investment Research cut Encore Capital Group from a “buy” rating to a “hold” rating in a report on Wednesday. ValuEngine cut Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Finally, Wedbush set a $26.00 target price on Urban Outfitters and gave the company a “hold” rating in a report on Friday, May 17th.
Shares of Cidara Therapeutics stock traded up $0.11 during mid-day trading on Wednesday, reaching $1.72. 187,344 shares of the stock traded hands, compared to its average volume of 58,662. The company has a 50-day moving average price of $1.63. Cidara Therapeutics has a fifty-two week low of $1.41 and a fifty-two week high of $5.00. The stock has a market capitalization of $42.89 million, a PE ratio of -0.74 and a beta of 2.19. The company has a quick ratio of 3.19, a current ratio of 3.19 and a debt-to-equity ratio of 0.04.
Cidara Therapeutics (NASDAQ:CDTX) last announced its earnings results on Thursday, May 9th. The biotechnology company reported ($0.60) EPS for the quarter, meeting analysts’ consensus estimates of ($0.60). As a group, analysts forecast that Cidara Therapeutics will post -2.22 earnings per share for the current fiscal year.
Large investors have recently bought and sold shares of the stock. BlackRock Inc. increased its holdings in shares of Cidara Therapeutics by 1.9% in the fourth quarter. BlackRock Inc. now owns 291,512 shares of the biotechnology company’s stock valued at $685,000 after purchasing an additional 5,563 shares during the last quarter. Two Sigma Investments LP increased its holdings in shares of Cidara Therapeutics by 96.6% in the fourth quarter. Two Sigma Investments LP now owns 29,349 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 14,421 shares during the last quarter. Raymond James & Associates increased its holdings in shares of Cidara Therapeutics by 38.2% in the fourth quarter. Raymond James & Associates now owns 331,351 shares of the biotechnology company’s stock valued at $779,000 after purchasing an additional 91,553 shares during the last quarter. Alethea Capital Management LLC grew its position in Cidara Therapeutics by 17.0% in the first quarter. Alethea Capital Management LLC now owns 564,313 shares of the biotechnology company’s stock worth $1,495,000 after acquiring an additional 81,956 shares during the period. Finally, Raymond James Financial Services Advisors Inc. grew its position in Cidara Therapeutics by 27.0% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 269,872 shares of the biotechnology company’s stock worth $634,000 after acquiring an additional 57,306 shares during the period. 60.33% of the stock is owned by hedge funds and other institutional investors.
About Cidara Therapeutics
Cidara Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates.
Recommended Story: Quick Ratio
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.